A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing…

Overview of attention for article published in International Journal of Clinical Oncology, May 2012

Altmetric Badge

Mentioned by

So far, Altmetric has seen 1 X post from an account with 363 followers.

[VEGF] A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients w... http://t.co/oSThC0O5 PM